Oncology trials still rely heavily on radiologists measuring a limited number of target lesions across serial scans. RECIST 1.1 created a common language for response, but a one-dimensional caliper cannot express every spatial, temporal or biological change inside a tumor.
Altis Labs is betting that routine imaging contains a richer signal. Its computational imaging models analyze longitudinal scans alongside outcomes data to estimate prognosis and detect treatment effects earlier. A $25 million Series A gives the company capital to move that thesis from retrospective validation toward a regulated clinical-trial endpoint layer.
In this deep dive, we are going to look at:
- Why this matters now: the limits of manual tumor measurement
- What Altis actually financed and demonstrated
- The obvious read versus the deeper signal
- A taxonomy of oncology-response methods
- The evidence ladder for regulatory qualification
- The HealthTech investor's signal
- The strongest technical counter-thesis
- Four observable milestones for 2027
- The bottom line for biopharma executives and investors
